Press Releases
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
May 16, 2013
Eisai Inc. announced today that nine abstracts highlighting new study results in melanoma, breast and endometrial cancer will be presented during...
-
May 16, 2013Will Lead Commercial Strategy for Eisai's Subsidiary in Mexico
Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., today announces the appointment of Ricardo Gonzalez Balboa to the position of...
-
May 16, 2013Data to Be Presented at Annual Meeting of the American Society of Clinical Oncology (ASCO)
Helsinn Group and Eisai Inc. announced today top-line results from Helsinn's pivotal clinical studies investigating the...
-
May 9, 2013
Eisai USA Foundation Inc., the charitable arm of Eisai Inc., announces that it has pledged a $1 million donation to the Conquer Cancer Foundation...
-
May 8, 2013
Eisai Inc. announced today that the U.S. Drug Enforcement Administration (DEA) has placed BELVIQ (pronounced BEL-VEEK) into Schedule IV of the...
-
Apr 18, 2013-- 4 Paws for Ability Service Dogs to Greet Visitors at Eisai Event Booth --
Woodcliff Lake, NJ - April 18, 2013 - Eisai Inc. announced today that it is a silver level sponsor of the Epilepsy Foundation's 7th Annual National Walk for Epilepsy, a family-oriented,...
-
Apr 11, 2013Newly Created Position to Strengthen Clinical Research
Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., today announces the immediate appointment of Lynn Kramer, MD, to the newly...
-
Mar 26, 2013
Eisai Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved ACIPHEX(®) Sprinkle™ Delayed-Release Capsules 5mg...
-
Mar 21, 2013- Companies to Provide Open Access to Information with Goal of Accelerating Discovery of Medicines for People Living with Difficult-to-Treat Cancers -
H3 Biomedicine Inc., a biopharmaceutical company specializing in the discovery and development of oncology treatments, and BGI,...
-
Feb 21, 2013
Woodcliff Lake, NJ and Montreal, Quebec, February 21, 2013 - Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., and Valeant Pharmaceuticals International, Inc. (NYSE/TSX: VRX)...